Atazanavir and cobicistat: new combination HIV drug

Evotaz, a combination drug consisting of the protease inhibitor atazanavir (Reyataz) and the pharmacoenhancer cobicistat (Tybost), has been launched by Bristol-Myers Squibb.

Further information
View Evotaz drug record 
Summary of Product Characteristics
Manufacturer: Bristol-Myers Squibb

The 300mg/150mg tablets are licensed in combination with other antiretrovirals for the treatment of HIV-1 infected patients without known mutations associated with atazanavir resistance.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

SGLT2 inhibitors: MHRA warns of Fournier's gangrene risk

SGLT2 inhibitors: MHRA warns of Fournier's gangrene risk

Cases of necrotising fasciitis of the genitalia or...

New advice for carbimazole over malformation and pancreatitis risks

New advice for carbimazole over malformation and pancreatitis risks

Reports of congenital malformations and acute pancreatitis...

Ophthalmic Preparations, Preservatives and Potential Sensitisers as Ingredients

Ophthalmic Preparations, Preservatives and Potential Sensitisers as Ingredients

Potential sensitising agents in eye drops and ointments.

Antibiotic Treatments in Adults, Summary of Regimens

Antibiotic Treatments in Adults, Summary of Regimens

Dose regimens for common bacterial infections.